Technology | Contrast Media | February 02, 2017

Lantheus Medical Imaging Announces FDA Approval of Definity Label Update

Label revision removes cardiac shunt contraindication

Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication

February 2, 2017 — Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity Vial for (Perflutren Lipid Microsphere) Injectable Suspension. The update removes the contraindication statement related to use in patients with a known or suspected cardiac shunt from the U.S. Prescribing Information.

Definity is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

A cardiac shunt is a pattern of blood flow in the heart that deviates from the normal path of the circulatory system, which may present in 10 to 35 percent of patients. These patients were previously excluded from receiving a valuable echo contrast study of the left ventricle. The FDA’s decision to remove the contraindication concerning known or suspected cardiac shunts was based on Lantheus’ submission referencing several publications and data supporting the safety of echocardiography contrast products in patients with cardiac shunts. Information concerning administration in patients with a cardiac shunt appears in the Warnings section of the Definity Prescribing Information.

Neil Weissman, M.D., president of MedStar Health Research Institute (Washington, D.C.), professor of medicine at Georgetown University and past president of the American Society of Echocardiography commented, “The echocardiography medical and scientific community has long demonstrated the safety of echocardiographic contrast agents through published clinical studies which has supported the removal of the contraindication for Definity in patients with cardiac shunts. This is particularly noteworthy as Definity is the most widely used echocardiography agent in the U.S. with published data supporting its safety profile across multiple care settings and across gender and race in adults, including those age 65 and older.”

Weissman continued, “This is an important step toward broader acceptance and appropriate use of echo contrast agents, which can safely and cost effectively provide critical information to help clinicians accurately diagnose and manage patients to achieve better outcomes.”

Up to 20 percent of all resting echocardiography studies and up to 30 percent of those conducted in critical care patients can result in suboptimal echocardiograms. A suboptimal image is one in which two or more contiguous left ventricular segments in any of the three apical views cannot be visualized. The use of contrast in suboptimal echocardiograms may help with clinical evaluation of the patient.

For more information: www.lantheus.com

Related Content

Clarius Demonstrates Point-of-Care Ultrasound for Disaster and Emergency Medicine
News | Ultrasound Imaging | April 25, 2017
Clarius Mobile Health will demonstrate its wireless, handheld ultrasound scanners at the World Association for Disaster...
GE Healthcare and Echosens Introduce Integrated Liver Package for Logiq S8 XDclear 2.0 Ultrasound
News | Ultrasound Imaging | April 19, 2017
To further support clinicians in their fight against chronic liver disease, Echosens and GE Healthcare have joined...
Cardiovascular Institute of the South Upgrades Cardiac Ultrasound With New Toshiba Medical Systems
News | Cardiovascular Ultrasound | April 17, 2017
April 17, 2017 — To bolster its technology and treatment capabilities for coronary and peripheral artery diseases acr
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
B. Braun, Philips, Xperius, ultrasound-guided regional anesthesia, vascular access, RSNA 2017
Technology | Ultrasound Imaging | April 06, 2017
April 6, 2017 — Philips announced a multi-year strategic alliance with B.
News | Prostate Cancer | April 04, 2017
Profound Medical Corp. announced that the first TULSA-PRO patient paid procedure has been successfully conducted at the...
ASE, EACVI, focused update document, aortic stenosis, AS, echocardiography, new classification scheme
News | Cardiovascular Ultrasound | April 03, 2017
The American Society of Echocardiography (ASE) and the European Association of Cardiovascular Imaging (EASCVI) have...
Analogic, bkFusion, bk3000, MRI-ultrasound fusion, prostate biopsy, EAU 2017
News | Biopsy Systems | March 30, 2017
March 30, 2017 — Analogic Corp.
Toshiba, Aplio i-series, MSK, musculoskeletal ultrasound, RSNA 2017
Technology | Ultrasound Imaging | March 29, 2017
March 29, 2017 — Toshiba Medical recently announced the launch of its new premium Aplio i-series...
prenatal ultrasound, decreased bone density, rabbit study, Pertanika Journal of Science & Technology
News | Ultrasound Imaging | March 28, 2017
March 28, 2017 — Young rabbits exposed to...
Overlay Init